Business Wire

Invivoscribe Launches Grant Program to Support Novel Applications for Sequence-Based Analyses of the Immune System

Share

Invivoscribe, a global leader in precision diagnostics, has announced the launch of an Immune Biomarker Discovery grant program, focused on supporting development, validation and deployment of novel applications for use of their distributed LymphoTrack® NGS products and bioinformatics software.

Massively parallel sequencing coupled with reagents targeting the immune receptor loci have accelerated our understanding of the immune response and immunology related disease processes. The availability of distributed RUO LymphoTrack tests and bioinformatics have eliminated a majority of the barriers of a service model approach, and have accelerated the ability to identify, track and monitor biomarkers associated with hematologic malignancies. These products are also being deployed worldwide to track the manufacture and treatment of immunotherapy, such as CAR T-cell therapies, and provide a comprehensive way to track a subject’s immune response to disease processes and to vaccines.

In conversations with customers and partners worldwide, we have also realized that our Research Use Only (RUO) LymphoTrack® sequencing kits and services also have utility far beyond clinical oncology, as these assays and software products are currently being used in research in areas as diverse as, studies of celiac disease and other autoimmune diseases, tracking the immune health of astronauts on the ISS, examining the immune response throughout the course of clinical treatments, and identifying changes in the immune repertoire with onset and progression of disease. Intrigued to learn what innovative applications our RUO LymphoTrack kits and services are being used for, we decided to launch this grant program to support these endeavors.

Successful innovative proposals submitted by applicants to our Invivoscribe’s Immune Biomarker Discovery grant program will receive LymphoTrack kits, controls and software to support their R&D project. Grants will be awarded to support cutting-edge research and development in academic, government and early-stage commercial laboratories conducting promising research studies.

“The combined costs of library preparation reagents, NGS sequencing reagents, and development of bioinformatics software represent an obstacle for researchers. The idea of this grant program is to reduce these financial barriers, thus empowering a few progressive laboratories to bring their groundbreaking applications to fruition,” says Tony Lialin, Chief Commercial Officer at Invivoscribe. Those selected as winners of the grant will not only receive NGS products, but will be provided additional opportunities to collaborate with Invivoscribe’s global network of ISO15189 accredited LabPMM laboratories. The laboratories selected for the grant program will also be featured in upcoming webinars and will be invited to speak at a number of symposiums around the world.

Details and How to Apply/Submit a Proposal

If your laboratory is interested in applying for Invivoscribe’s Immune Biomarker Discovery grant program to improve the standard of healthcare, we encourage you to submit research proposals that focus on the development of engineered antibodies to target antigens of infectious pathogens, toxins, allergens, and malignant diseases such as cancer and autoimmune disorders. More information about the program and details about how to submit a proposal can be found at www.invivoscribe.com/NGS-Grant. Proposals will be accepted from qualified laboratories across the world through Aug. 31, 2021 and winners will be announced by September 30, 2021. Additional information about the grant program and our oncology products and services can be requested by emailing sales@invivoscribe.com.

About Invivoscribe

Invivoscribe has been Improving Lives with Precision Diagnostics® for more than twenty-five years, advancing the field of precision medicine by developing and providing standardized reagents, tests, and bioinformatics tools to more than 700 customers in 160 countries. Invivoscribe has significantly impacted global health, working with pharmaceutical companies to accelerate approvals of new drugs and treatments by supporting international clinical trials, developing, commercializing companion diagnostics, and providing expertise in both regulatory and laboratory services. With its proven ability to provide global access to distributable reagents, kits, and controls, as well as clinical trial services through our international clinical lab subsidiaries (LabPMM), Invivoscribe has demonstrated it is an ideal partner. For additional information please visit us at www.invivoscribe.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Tony Lialin
inquiry@invivoscribe.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Jetcraft Releases 5-year Pre-Owned Market Forecast Exploring New Era for Business Aviation1.12.2021 17:00:00 CET | Press release

Jetcraft, the world leader in business jet sales and acquisitions, is releasing its 5-Year Pre-Owned Business Aviation Market Forecast, introducing an enhanced data-driven methodology recognizing potential market opportunities and incorporating a greater number of global trends. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211201005802/en/ Jetcraft’s Owner and Chairman of the Board, Jahid Fazal-Karim (Photo: Business Wire) Jetcraft’s 2021 Market Forecast predicts pre-owned aircraft transaction volume and value will maintain their current healthy growth rates, reaching 2,647 transactions valued at $12.4B annually by 2025. Jahid Fazal-Karim, Owner and Chairman of the Board at Jetcraft, says: “Since the pandemic, the true benefits of business aviation have been realized, particularly by new entrants who have had the means to fly privately but never previously the inclination, and we have seen our industry thrive. “The combina

Neustar Security Services Spins Out with Focused Investment to Foster Accelerated Growth1.12.2021 15:46:00 CET | Press release

Neustar Security Services, LLC (“Neustar Security Services”), a leading global provider of cloud-oriented security services that enable global business to thrive online, has become the newest portfolio company of Golden Gate Capital and GIC following the completed sale of Neustar Inc.’s (“Neustar”) Marketing, Risk and Communications solutions businesses to TransUnion. The spin out marks Neustar Security Services’ entry into its next phase of growth with the focused backing of its investors and strong continuity of leadership. Brian McCann, who has served as President of Neustar’s Security business since 2019, has been appointed CEO of Neustar Security Services and will lead the company’s more than 250 employees. Neustar President and CEO, Charlie Gottdiener, will serve as a Director on the Neustar Security Services Board of Directors. In addition to McCann, the Company’s senior leadership team will include Anthony Chadd, Senior Vice President and Chief Revenue Officer; Carlos Morales,

Dominik Belloin Joins biolog-id’s Board of Directors1.12.2021 15:32:00 CET | Press release

Biolog-id, a global leader in the traceability of sensitive therapeutic products, has just co-opted Dominik BELLOIN within the company’s board. He will sit alongside Pierre Lesourd, Jean-Louis Colders, Jacques Simonnet and Jean-Claude Mongrenier. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211201005699/en/ Dominik Belloin joins biolog-id's board of directors (Photo: Business Wire) Graduated from ESSEC and Harvard Business School (MBA), Dominik Belloin began his career at Goldman Sachs in 1987 in New York City, then in London as Associate and then Executive Director of Corporate Finance. He then joined the Bertelsmann Group where he held several senior management positions before becoming CFO of the RTL Group in Luxembourg. In 2000, he was appointed Managing Director of Merrill Lynch with responsibility for investment banking for the media sector in Europe. In 2003, Dominik Belloin became a member of the Executive Committe

Apave, ESI Group and Onet Technologies – A unique alliance for an outstanding EPR project at the Jaitapur site in India1.12.2021 15:15:00 CET | Press release

Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211201005681/en/ (Photo: Business Wire) Apave, ESI Group (Paris:ESI) and Onet Technologies have formalized, at the WNE (World Nuclear Exhibition) 2021, their collaboration, through the MINS (Make in India Nuclear supply chain Support) alliance, to build a common value proposition in order to respond to the project to create six EPR reactors on the Jaitapur site in western India. Philippe Maillard, CEO of APAVE Group, Emmanuel Leroy, EVP Product, Innovation & Industry Solutions of ESI Group and Alain Gauvin, CEO of ONET Technologies, signed today at WNE 2021, with the participation of Xavier Ursat, Group Senior Executive Vice President, New Nuclear Projects and Engineering, a joint declaration of intent structuring the MINS alliance, thus combining their skills on the outstanding Indian EPR market at the Jaitapur site. A unique Indian project In April 2021, EDF s

Aurora Accelerates Development of the Aurora Driver with AWS1.12.2021 15:00:00 CET | Press release

Today, Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company (NASDAQ: AMZN), announced that Aurora (NASDAQ: AUR), a leader in self-driving vehicle technology, has selected AWS as its preferred cloud provider for machine learning training and cloud-based simulation workloads. Aurora uses AWS’s proven infrastructure and unparalleled portfolio of capabilities to safely accelerate the development of the Aurora Driver, its scalable self-driving vehicle technology. The Aurora Driver consists of sensors that perceive the world, software that plans a safe path through it, and a computer that powers and integrates Aurora’s hardware and software with any vehicle platform. For its machine learning training and cloud-based simulation workloads, Aurora is all-in on AWS, and it uses the cloud to process trillions of data points each day. Now, the company is scaling its training workloads in the cloud to complete up to 12 million physics-based driving simulations per day by the end of the year

PPG Launches Expanded Automotive OEM Clearcoat Production in Germany1.12.2021 14:49:00 CET | Press release

PPG (NYSE: PPG) today announced the start-up of expanded automotive OEM clearcoat production at its facility in Erlenbach, Germany. The €3 million project nearly doubles the site’s capacity for premium clearcoats and uses advanced manufacturing technology to improve operational efficiency, sustainability and flexibility compared to conventional processes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211201005623/en/ PPG business and site leaders celebrate the opening of the expanded clearcoat facility in Erlenbach. (Photo: Business Wire) “This is an important investment that ensures we will continue to meet the growing regional demand for our premium clearcoats, which offer the world-class finish with superior appearance and durability that our customers demand,” said Roald Johannsen, PPG vice president, automotive OEM coatings, Europe, Middle East and Africa. “Using advanced manufacturing technology also gives us increase

Selig Group Announces Acquisition of MGJ; Second Announced Acquisition this Year1.12.2021 14:45:00 CET | Press release

Selig Group (“Selig”), owned by CC Industries (“CCI”), announced today that it has acquired Manufacture Générale de Joints (“MGJ”). Founded in 1947 and headquartered near Lyon, France, MGJ is a leading supplier of foam-based liners worldwide. Through decades of investment, MGJ has developed differentiated foam-based products for an expansive range of applications. The combination provides Selig with highly complementary adjacent capabilities to serve its customers more broadly on a global basis and will accelerate the combined development of environmentally sustainable products. This is Selig’s second acquisition in the last year and reflects its strategy to augment growth and expand its business model via complementary solutions. “MGJ is an excellent company and shares Selig’s passion for developing technically-differentiated solutions to customers' problems,” said Bill Crown, President and Chief Executive Officer of CCI. “We look forward to supporting Selig’s continued growth globall

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom